In response to the outbreak of COVID-19 and in order to meet the huge market demand for corona vaccine both for domestic China as abroad, SmithBio will expand its Huangshan manufacturing plant. The new state-of-the-art building of approximately 1000㎡ will accommodate manufacturing of large-scale bioreactor systems (> 5000L). Construction is planned to start after the 2021 Year vacation and will enable SmithBio to satisfy the growing domestic and international demand for customized cGMP compliant high-quality products within the shortest timeframe.